These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38037148)

  • 1. Cardiovascular disease risk in early rheumatoid arthritis: the impact of cartilage oligomeric matrix protein (COMP) and disease activity.
    Rydell E; Jacobsson LT; Saxne T; Turesson C
    BMC Rheumatol; 2023 Dec; 7(1):43. PubMed ID: 38037148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of rheumatoid arthritis on the risk of cerebrovascular disease and coronary artery disease in young adults.
    Chen YR; Hsieh FI; Chang CC; Chi NF; Wu HC; Chiou HY
    J Chin Med Assoc; 2018 Sep; 81(9):772-780. PubMed ID: 29861211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating Interleukin 17A and Other Inflammatory Proteins May Predict Cardiovascular Disease in Early Rheumatoid Arthritis.
    Rydell E; Jacobsson LTH; Turesson C
    J Rheumatol; 2024 Aug; 51(8):752-758. PubMed ID: 38692670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cartilage oligomeric matrix protein (COMP): the role of a non-collagen cartilage matrix protein as a marker of disease activity and joint destruction in patients with rheumatoid arthritis and osteoarthritis].
    Marti C; Neidhart M; Gerber T; Hauser N; Michel BA; Häuselmann HJ
    Z Rheumatol; 1999 Apr; 58(2):79-87. PubMed ID: 10408068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis and its correlation with sonographic knee cartilage thickness and disease activity.
    Sakthiswary R; Rajalingam S; Hussein H; Sridharan R; Asrul AW
    Clin Rheumatol; 2017 Dec; 36(12):2683-2688. PubMed ID: 28889184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decrement of serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis (RA) patients achieving remission after 6 months of etanercept treatment: comparison with CRP, IgM-RF, MMP-3 and anti-CCP Ab.
    Kawashiri SY; Kawakami A; Ueki Y; Imazato T; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Nakamura H; Origuchi T; Ida H; Eguchi K
    Joint Bone Spine; 2010 Oct; 77(5):418-20. PubMed ID: 20864374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time-averaged DAS28 and HAQ predict cardiovascular disease in patients with rheumatoid arthritis: Data from KORONA registry.
    Min HK; Kim HR; Lee SH; Kang KY; Park SH; Kwok SK
    Joint Bone Spine; 2022 Oct; 89(5):105401. PubMed ID: 35513231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early increase in serum-COMP is associated with joint damage progression over the first five years in patients with rheumatoid arthritis.
    Andersson ML; Svensson B; Petersson IF; Hafström I; Albertsson K; Forslind K; Heinegård D; Saxne T
    BMC Musculoskelet Disord; 2013 Aug; 14():229. PubMed ID: 23915292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between cartilage oligomeric matrix protein (COMP) and rheumatoid arthritis severity.
    Saghafi M; Khodashahi M; Saadati N; Azarian A; Rezaieyazdi Z; Salehi M; Sahebari M
    Electron Physician; 2017 Dec; 9(12):5940-5947. PubMed ID: 29560145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum and synovial cartilage oligomeric matrix protein levels in early and established rheumatoid arthritis.
    El Defrawy AO; Gheita TA; Raslan HM; El Ansary MM; El Awar AH
    Z Rheumatol; 2016 Nov; 75(9):917-923. PubMed ID: 26683321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease factors in early rheumatoid arthritis are associated with differential risks for cardiovascular events and mortality depending on age at onset: a 10-year observational cohort study.
    Ajeganova S; Andersson ML; Frostegård J; Hafström I
    J Rheumatol; 2013 Dec; 40(12):1958-66. PubMed ID: 23950188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis and knee osteoarthritis.
    Wisłowska M; Jabłońska B
    Clin Rheumatol; 2005 Jun; 24(3):278-84. PubMed ID: 15940561
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigating changes in disease activity as a mediator of cardiovascular risk reduction with methotrexate use in rheumatoid arthritis.
    Johnson TM; Sayles HR; Baker JF; George MD; Roul P; Zheng C; Sauer B; Liao KP; Anderson DR; Mikuls TR; England BR
    Ann Rheum Dis; 2021 Nov; 80(11):1385-1392. PubMed ID: 34049859
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Derivation and internal validation of a multi-biomarker-based cardiovascular disease risk prediction score for rheumatoid arthritis patients.
    Curtis JR; Xie F; Crowson CS; Sasso EH; Hitraya E; Chin CL; Bamford RD; Ben-Shachar R; Gutin A; Flake DD; Mabey B; Lanchbury JS
    Arthritis Res Ther; 2020 Dec; 22(1):282. PubMed ID: 33276814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-Reactive Protein and Risk of Cardiovascular Events and Mortality in Patients with Various Cardiovascular Disease Locations.
    Burger PM; Pradhan AD; Dorresteijn JAN; Koudstaal S; Teraa M; de Borst GJ; van der Meer MG; Mosterd A; Ridker PM; Visseren FLJ;
    Am J Cardiol; 2023 Jun; 197():13-23. PubMed ID: 37218417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can tocilizumab decrease cartilage oligomeric matrix protein levels and disease activity in patients with long-standing rheumatoid arthritis?
    Benucci M; Meacci F; Manfredi M; Gobbi FL; Infantino M; Ricci C; Sarzi-Puttini P; Atzeni F
    Curr Rheumatol Rev; 2014; 10(2):131-5. PubMed ID: 25599685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comorbidity burden and clinical characteristics of patients with difficult-to-control rheumatoid arthritis.
    Batko B; Urbański K; Świerkot J; Wiland P; Raciborski F; Jędrzejewski M; Koziej M; Cześnikiewicz-Guzik M; Guzik TJ; Stajszczyk M
    Clin Rheumatol; 2019 Sep; 38(9):2473-2481. PubMed ID: 31076943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients.
    Arts EE; Fransen J; den Broeder AA; Popa CD; van Riel PL
    Ann Rheum Dis; 2015 Jun; 74(6):998-1003. PubMed ID: 24458537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of Cardiovascular Disease Associated with a Restless Legs Syndrome Diagnosis in a Retrospective Cohort Study from Kaiser Permanente Northern California.
    Van Den Eeden SK; Albers KB; Davidson JE; Kushida CA; Leimpeter AD; Nelson LM; Popat R; Tanner CM; Bibeau K; Quesenberry CP
    Sleep; 2015 Jul; 38(7):1009-15. PubMed ID: 26083613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low disease activity (DAS28≤3.2) reduces the risk of first cardiovascular event in rheumatoid arthritis: a time-dependent Cox regression analysis in a large cohort study.
    Arts EE; Fransen J; Den Broeder AA; van Riel PLCM; Popa CD
    Ann Rheum Dis; 2017 Oct; 76(10):1693-1699. PubMed ID: 28606965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.